目的：评估和探讨应用免疫吸附治疗常规一线免疫治疗方案效果不佳的急性重症/难治性吉兰-巴雷 综合征患者的疗效及安全性。方法：选择急性重症/难治性吉兰-巴雷综合征患者6例，均为常规一线免疫治 疗效果不佳，后续给予蛋白A免疫吸附治疗。回顾性分析6例患者的临床资料、治疗情况及疗效、免疫球蛋 白和补体变化及不良反应。 结果：免疫吸附治疗后，6例患者的临床症状、体征均有改善，包括肌力、自主呼 吸功能、眼球运动和意识状态等不同方面；6例患者的IgG水平在首次免疫吸附治疗后均显著下降，IgM、 IgA、补体C3和C4亦有不同程度下降；6例患者中仅2例出现轻微不良反应。结论：急性重症/难治性吉兰- 巴雷综合征患者应用常规一线免疫治疗未达满意疗效，继以免疫吸附治疗可能有助于改善患者神经功能， 提高生存质量，且安全性良好。

To evaluate and explore the efficacy and safety of immunoadsorption treatment in patients with acute severe/refractory Guillain-Barré syndrome (GBS) who have unsatisfactory responses to conventional first-line immunotherapy. Methods: Six patients with acute severe/refractory GBS who had poor responses to conventional first-line immunotherapy were selected and subsequently received protein A immunoadsorption treatment. The clinical data, treatment conditions, efficacy, changes in immunoglobulins and complements, and adverse reactions of the six patients were retrospectively analyzed. Results: After immunoadsorption treatment, the clinical symptoms and signs of the six patients were improved, including muscle strength, spontaneous breathing function, eye movement, and consciousness state among other aspects. The IgG levels of the six patients significantly decreased after the first immunoadsorption treatment, and the IgM, IgA, complement C3, and C4 also decreased to varying degrees. Only two of the six patients experienced mild adverse reactions. Conclusion: For patients with acute severe/refractory GBS who do not achieve satisfactory results with conventional first-line immunotherapy, subsequent immunoadsorption treatment may help improve neurological function, enhance the quality of life, and has good safety.